Company / Shareholders' Equity
Ginkgo Bioworks Holdings, Inc. Shareholders' Equity History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$508.6M
FY2025
5-year range
$508.6M / $1.7B
FY2021-FY2025
Trend
-29.0%
vs FY2024
Sector context
#96 of 215
Health Care
What the data says
At $509M, Ginkgo Bioworks Holdings, Inc.'s shareholders' equity ranks #96 of 215 in the Health Care sector. Shareholders' Equity has declined for 3 consecutive years, from $1.7B in FY2022 to $509M in FY2025.
Based on SEC 10-K filings.
$509M in FY2025 with a 5-year CAGR of +1.6%.
Declined from $1.1B to $509M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -33.6%
- 5-Year CAGR
- +1.6%
- 10-Year CAGR
- -
Sector benchmark
#96 of 215 in Health CareTop 45% of 215This company $508.6M Sector average $2.6B
▼
-80.1% below sector average
Key checks
Key Insights
- Ginkgo Bioworks Holdings, Inc.'s shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of +1.6%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 29.0% year-over-year.
- Ranks #96 out of 215 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $508.6M | -29.0% |
| FY2024 | $716.1M | -34.7% |
| FY2023 | $1.1B | -36.8% |
| FY2022 | $1.7B | +15.3% |
| FY2021 | $1.5B | +220.3% |
| FY2020 | $470.1M | -6.3% |
| FY2019 | $501.9M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026